- $227.15m
- -$183.45m
- 43
- 46
- 15
- 26
Annual balance sheet for Acelyrin, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 102 | 315 | 721 | 448 |
| Net Total Receivables | 0 | 0.388 | 4.75 | 30.2 |
| Prepaid Expenses | ||||
| Total Current Assets | 102 | 316 | 737 | 481 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | — | — | 3.37 | 8.39 |
| Other Long Term Assets | ||||
| Total Assets | 102 | 320 | 743 | 491 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 11.7 | 15.9 | 85.2 | 26.6 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 11.7 | 26.2 | 86.4 | 32.8 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 90.6 | 294 | 656 | 458 |
| Total Liabilities & Shareholders' Equity | 102 | 320 | 743 | 491 |
| Total Common Shares Outstanding |